{"text_format":"3","workbook":"xlsx","n_sheets":6,"sheets":["CRP","primary composite endpoint","death","MI","stroke","GI"],"read":"whole","date_system":"1900"}

{"sheet":"CRP","index":0,"n_rows":15,"n_cols":32,"rows_kept":15}
["ID","Author ","year","country","designe","participants disease","intervention details","dose of colchicine (mg daily)","control","age inv","SD","age control","SD","duration colch (month)","duration follow (month)","sex","intev N","control N","outcome presentation","interventin_Pre","SD_inv_pre","intervention_Post","SD_inv_post","Change_inv","SD_change_inv","Control_pre","SD_cont_pre","Control_post","SD","Change_cont","SD_change_cont","description"]
[1,"Mariama Akodad",2016,"France","parallel","STEMI",null,1,"optimal medical treatment alone",60.1,13.1,59.7,11.4,1,1,"both",23,21,"mean of peak",null,null,29.03,25.56,{"$nulls":4},21.86,25.39]
[2,"Thomas Hennessy",2019,"Australia.","parallel","type 1 acute MI (by the\n3rd universal definition",null,0.5,"Placebo",61,13.6,61,12.5,1,1,"both",119,118,"median(interquartile range)",6.9,"3.1,14.8   ",1.6," 0.7,3.5"," −4.3 "," −1.1 , −14.1",7.7," 3.0,18.9",2," 0.9,4.0","−3.3"," −0.9 , −14.4"]
[3,"Nina C. Raju",2011,null,"parallel","acute coronary syndromes or acute ischemic stroke",null,1,"placebo",57.2,11.7,57.2,8.7,1,1,"both",31,37,"mean±SD",null,null,7.2,28.9,12.2,23.9,null,null,2.9,4.6,20.9,34.9," Change has been reported as delta. consider negative sign if necessary."]
[4,"Spyridon Deftereos",2015,"Greece","parallel","STEMI","starting with a\nloading dose of 2 mg (1.5 mg initially followed by 0.5 mg 1 hour\nlater) and continuing with 0.5 mg twice daily",1.2,"placebo",58,"52-64",58,"51-68",0.16,0.16,"both",77,74,"median of peak (interquartile)",null,null,42.9,"16.3,71.4",{"$nulls":4},63.8,"34.7,103.4"]
[5,"Trisulo Wasyanto1",2018,"Indonesia","parallel","Acute Myocardial\nInfarction",null,0.5,"placebo",57.87,null,52.87,null,0.16,0.16,"both",16,16,"mean±SD",6.13,2.65,null,null,"̶  3.82",2.2,4.78,3.45,null,null,"̶  0.57",3.12,"delta hsCRP has been reported positive in table but in the text the word decrease has been used"]
[6]
[7]
[7]
[8]
[9]
[10]
[11]
[12]
[13]

{"sheet":"primary composite endpoint","index":1,"n_rows":15,"n_cols":22,"rows_kept":15,"merged":[[2,0,3,0],[2,21,3,21],[2,22,3,22],[2,23,3,23]]}
["ID","Author ","year","country","designe","participants disease","intervention details","dose of colchicine (mg daily)","control","age inv","SD","age control","SD","duration colch  (MONTH)","duration follow (MONTH)","sex","intev N","control N","intev N","control N","HR","description"]
[1,"Jean‑Claude Tardif",2019,"international","parallel","myocardial infarction",null,0.5,"placebo",60.6,10.7,60.5,10.6,19.5,22.6,"both",2366,2379,132,142]
[2,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months,",0.54,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,12,"both",396,399,15,11]
[null,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months,",0.49,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,13.33,"both",396,399,15,12]
[3,"Thomas Hennessy",2019,"Australia.","parallel","type 1 acute MI (by the\n3rd universal definition",null,0.5,"Placebo",61,13.6,61,12.5,1,1,"both",119,118,0,2]
[4,"Nina C. Raju",2011,null,"parallel","acute coronary syndromes or acute ischemic stroke",null,1,"placebo",57.2,11.7,57.2,8.7,1,1,"both",36,38,1,0]
[5,"Mariama Akodad",2016,"France","parallel","STEMI",null,1,"optimal medical treatment alone",60.1,13.1,59.7,11.4,1,1,"both",23,21,0,1]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]

{"sheet":"death","index":2,"n_rows":15,"n_cols":22,"rows_kept":15,"merged":[[2,0,3,0],[2,21,3,21],[2,22,3,22],[2,23,3,23]]}
["ID","Author ","year","country","designe","participants disease","intervention details","dose of colchicine (mg daily)","control","age inv","SD","age control","SD","duration colch  (MONTH)","duration follow (MONTH)","sex","intev N","control N","intev N of death","control N of death","HR","description"]
[1,"Jean‑Claude Tardif",2019,"international","parallel","myocardial infarction",null,0.5,"placebo",60.6,10.7,60.5,10.6,19.5,22.6,"both",2366,2379,43,44,0.98]
[2,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months,",0.54,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,12,"both",396,399,8,1,8.2]
[null,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months,",0.49,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,13.33,"both",396,399,8,1,8.2]
[3,"Thomas Hennessy",2019,"Australia.","parallel","type 1 acute MI (by the\n3rd universal definition",null,0.5,"Placebo",61,13.6,61,12.5,1,1,"both",119,118,0,0,null,"vital status of 2 patients who\nwere lost to trial follow-up was uncertain"]
[4,"Nina C. Raju",2011,null,"parallel","acute coronary syndromes or acute ischemic stroke",null,1,"placebo",57.2,11.7,57.2,8.7,1,1,"both",36,38,0,0]
[5,"Mariama Akodad",2016,"France","parallel","STEMI",null,1,"optimal medical treatment alone",60.1,13.1,59.7,11.4,1,1,"both",23,21,0,0]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]

{"sheet":"MI","index":3,"n_rows":16,"n_cols":21,"rows_kept":16,"merged":[[4,0,5,0],[4,21,5,21]]}
["ID","Author ","year","country","designe","participants disease","intervention details","dose of colchicine (mg daily)","control","age inv","SD","age control","SD","duration colch (MONTH)","duration follow (MONTH)","sex","intev N","control N","intev N  of MI","control N  of MI","HR"]
[1,"Jean‑Claude Tardif",2019,"international","parallel","myocardial infarction",null,0.5,"placebo.",60.6,10.7,60.5,10.6,19.5,22.6,"both",2366,2379,89,98,0.91]
[2,"Thomas Hennessy",2019,"Australia.","parallel","type 1 acute MI (by the\n3rd universal definition",null,0.5,"Placebo",61,13.6,61,12.5,1,1,"both",119,118,0,2]
[3,"Nina C. Raju",2011,null,"parallel","acute coronary syndromes or acute ischemic stroke",null,1,"placebo",57.2,11.7,57.2,8.7,1,1,"both",36,38,1,0]
[4,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months,",0.54,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,12,"both",396,399,7,10]
[null,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months,",0.49,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,13.33,"both",396,399,7,11]
[5,"Mariama Akodad",2016,"France","parallel","STEMI",null,1,"optimal medical treatment alone",60.1,13.1,59.7,11.4,1,1,"both",23,21,0,1]
[6]
[7]
[7]
[8]
[9]
[10]
[11]
[12]
[13]

{"sheet":"stroke","index":4,"n_rows":16,"n_cols":21,"rows_kept":16,"merged":[[2,0,3,0],[2,23,3,23]]}
["ID","Author ","year","country","designe","participants disease","intervention details","dose of colchicine (mg daily)","control","age inv","SD","age control","SD","duration colch  (MONTH)","duration follow(MONTH)","sex","intev N","control N","intev N  of stroke","control N of stroke","HR"]
[1,"Jean‑Claude Tardif",2019,"international","parallel","myocardial infarction",null,0.5,"placebo.",60.6,10.7,60.5,10.6,19.5," 22.6\n","both",2366,2379,5,19,0.26]
[2,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months",0.54,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,12,"both",396,399,2,5,0.41]
[null,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months",0.49,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,13.33,"both",396,399,2,6,0.34]
[3,"Nina C. Raju",2011,null,"parallel","acute coronary syndromes or acute ischemic stroke",null,1,"placebo",57.2,11.7,57.2,8.7,1,1,"both",36,38,0,1]
[4]
[5]
[6]
[7]
[7]
[8]
[9]
[10]
[11]
[12]
[13]

{"sheet":"GI","index":5,"n_rows":16,"n_cols":22,"rows_kept":16}
["ID","Author ","year","country","designe","participants disease","intervention details","dose of colchicine (mg daily)","control","age inv","SD","age control","SD","duration colch (MONTH)","duration follow (MONTH)","sex","intev N","control N","intev N  outcome","control N outcome","HR","description"]
[1,"Thomas Hennessy",2019,"Australia.","parallel","type 1 acute MI (by the\n3rd universal definition",null,0.5,"Placebo",61,13.6,61,12.5,1,1,"both",119,118,12,6]
[2,"Mariama Akodad",2016,"France","parallel","STEMI",null,1,"optimal medical treatment alone",60.1,13.1,59.7,11.4,1,1,"both",23,21,10,0,null,"no placebo"]
[3,"Spyridon Deftereos",2015,"Greece","parallel","STEMI","starting with a\nloading dose of 2 mg (1.5 mg initially followed by 0.5 mg 1 hour\nlater) and continuing with 0.5 mg twice daily",1.2,"placebo",58,"52-64",58,"51-68",0.16,0.16,"both",77,74,18,1]
[4,"Nina C. Raju",2011,null,"parallel","acute coronary syndromes or acute ischemic stroke",null,1,"placebo",57.2,11.7,57.2,8.7,1,1,"both",36,38,14,7]
[5,"David C. Tong",2020,"Australia","parallel","ACS","0.5mg oral colchicine twice daily for the first month, followed by 0.5mg daily for eleven months,",0.54,"placebo in addition to standard secondary prevention therapies",59.7,10.2,60,10.4,12,13.33,"both",396,399,91,83]
[6,"Jean‑Claude Tardif",2019,"international","parallel","myocardial infarction",null,0.5,"placebo.",60.6,10.7,60.5,10.6,19.5,22.6,"both",2330,2346,408,414]
[6]
[7]
[7]
[8]
[9]
[10]
[11]
[12]
[13]